202 related articles for article (PubMed ID: 18989161)
1. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
Davidsen ML; Dalhoff K; Schmiegelow K
J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
[TBL] [Abstract][Full Text] [Related]
2. Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia.
Wesolowska A; Dalgaard MD; Borst L; Gautier L; Bak M; Weinhold N; Nielsen BF; Helt LR; Audouze K; Nersting J; Tommerup N; Brunak S; Sicheritz-Ponten T; Leffers H; Schmiegelow K; Gupta R
Leukemia; 2011 Jun; 25(6):1001-6. PubMed ID: 21415851
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
Ansari M; Krajinovic M
Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.
Aplenc R; Lange B
Br J Haematol; 2004 May; 125(4):421-34. PubMed ID: 15142113
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
Yang JJ; Bhojwani D
Methods Mol Biol; 2013; 999():273-84. PubMed ID: 23666706
[TBL] [Abstract][Full Text] [Related]
6. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.
Coulthard SA; Matheson EC; Hall AG; Hogarth LA
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1385-91. PubMed ID: 15571264
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of childhood acute lymphoblastic leukemia.
Brenner TL; Pui CH; Evan WE
Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of acute leukemia.
Ansari M; Krajinovic M
Pharmacogenomics; 2007 Jul; 8(7):817-34. PubMed ID: 18240908
[TBL] [Abstract][Full Text] [Related]
9. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.
Marino S; Verzegnassi F; Tamaro P; Stocco G; Bartoli F; Decorti G; Rabusin M
Pediatr Blood Cancer; 2009 Dec; 53(6):984-91. PubMed ID: 19621425
[TBL] [Abstract][Full Text] [Related]
10. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.
Niedzielska E; Węcławek-Tompol J; Matkowska-Kocjan A; Chybicka A
Adv Clin Exp Med; 2013; 22(4):579-84. PubMed ID: 23986219
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):699-719. PubMed ID: 24673379
[TBL] [Abstract][Full Text] [Related]
13. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
[TBL] [Abstract][Full Text] [Related]
14. Inheritance and clinical outcome in childhood acute lymphoblastic leukemia.
Jamroziak K; Robak T
Leuk Res; 2009 Jul; 33(7):889-90. PubMed ID: 19243820
[No Abstract] [Full Text] [Related]
15. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
[TBL] [Abstract][Full Text] [Related]
16. [New techniques for optimization of thiopurine therapy in leukemia and transplantation].
Loennechen T; Lysaa RA; Giverhaug T; Sylte I; Mathiesen LE; Aarbakke J
Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1107-10. PubMed ID: 12043054
[TBL] [Abstract][Full Text] [Related]
17. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia.
Takanashi M; Morimoto A; Yagi T; Kuriyama K; Kano G; Imamura T; Hibi S; Todo S; Imashuku S
Haematologica; 2003 Nov; 88(11):1238-44. PubMed ID: 14607752
[TBL] [Abstract][Full Text] [Related]
18. TotalPlex gene amplification using bulging primers for pharmacogenetic analysis of acute lymphoblastic leukemia.
Kang HJ; Oh Y; Chun SM; Seo YJ; Shin HY; Kim CW; Ahn HS; Han BD
Mol Cell Probes; 2008 Jun; 22(3):193-200. PubMed ID: 18385010
[TBL] [Abstract][Full Text] [Related]
19. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
Kager L
J BUON; 2009 Sep; 14 Suppl 1():S181-6. PubMed ID: 19785064
[TBL] [Abstract][Full Text] [Related]
20. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.
Wang L; Weinshilboum R
Oncogene; 2006 Mar; 25(11):1629-38. PubMed ID: 16550163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
